Argo Wealth Advisory’s Pfizer PFE Stock Holding History

Argo Wealth Advisory’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Sell	88,538 -2,753	-3%	-$72K	1.18%	31
2026 Q1	$2.56M	Buy	91,291 +28,751	+46%	+$765K	1.5%	22
2025 Q4	$1.56M	Buy	+62,540	New	+$1.58M	0.93%	38

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Argo Wealth Advisory's PFE Position: Q2 2026 in Review

Argo Wealth Advisory reduced its Pfizer (PFE) stake by 3% in Q2 2026, selling an estimated $72K and leaving 88,538 shares worth $2.13M. The position accounts for 1.18% of the portfolio, ranked #31.

Argo Wealth Advisory first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.56M in Q1 2026. 2,814 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Argo Wealth Advisory held 88,538 shares of Pfizer worth $2.13M as of Q2 2026.
Argo Wealth Advisory sold 2,753 Pfizer shares in Q2 2026, an estimated $72K.
Pfizer made up 1.18% of Argo Wealth Advisory's portfolio in Q2 2026, its #31 holding.
Argo Wealth Advisory first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
Argo Wealth Advisory's Pfizer position peaked at $2.56M in Q1 2026.
2,814 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Argo Wealth Advisory's 13F filing for Q2 2026, filed 7 Aug 2026.